Benzinga

Benzinga

Benzinga

domingo, agosto 30

NRX Pharmaceuticals Inc

NRXPNASDAQ
Trade with Public
Trade with Public
$3.55
-0.07-1.93%
al cierre: Aug 28, 5:00 PM EST
$3.51
-0.037-1.04%
After hour: Aug 28, 7:55 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

NRX Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for NRX Pharmaceuticals (NRXP).

Price Target Range — 10 Quarters

Analyst Consensus — 5 Analysts

5Buy
Consensus RatingBuy# Analysts5Avg. Consensus PT$29Upside to Avg. PT+737.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 25, 2026HC Wainwright & Co.Patrick R. TrucchioMaintainedBuy$45
Aug 18, 2026BTIGThomas ShraderMaintainedBuy$10
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $45 price target.
Benzinga Newsdesk

PRO
BTIG Maintains Buy on NRX Pharmaceuticals, Lowers Price Target to $10

BTIG analyst Thomas Shrader maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and lowers the price target from $25 to $10.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $45 price target.
Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $49

Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $48 to $49.
Benzinga Newsdesk

PRO
BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $25 Price Target

BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $25 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $45

HC Wainwright & Co. analyst Patrick R. Trucchio maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $40 to $45.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved